PubRank

Afschin Gandjour

Author PubWeight™ 28.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000. Diabetes Care 2004 1.01
2 Costs of dialysis--a regional population-based analysis. Nephrol Dial Transplant 2009 0.88
3 Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women. Value Health 2009 0.82
4 Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review. Value Health 2012 0.81
5 Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. Int J Technol Assess Health Care 2010 0.79
6 Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe. Expert Rev Pharmacoecon Outcomes Res 2014 0.79
7 Survivor costs in cost-effectiveness analysis. Ann Intern Med 2006 0.79
8 Modifiable behavioral factors as causes of death. JAMA 2004 0.78
9 Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Appl Health Econ Health Policy 2008 0.78
10 The ethics of non-inferiority trials. Lancet 2008 0.78
11 Direct costs of care in germany for children and adolescents with diabetes mellitus in the early course after onset. J Pediatr Endocrinol Metab 2004 0.78
12 Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation. Eur J Health Econ 2012 0.77
13 Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model. PLoS One 2011 0.77
14 Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease. Expert Rev Pharmacoecon Outcomes Res 2011 0.77
15 Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics 2008 0.76
16 Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis. Appl Health Econ Health Policy 2011 0.76
17 To treat or not to treat? Cost-effectiveness of ace inhibitors in non-diabetic advanced renal disease - a Dutch perspective. Kidney Blood Press Res 2013 0.75
18 Informing patients of their coronary risk. Arch Intern Med 2008 0.75
19 A payer's perspective on the cost effectiveness of gastric bypass surgery. Am J Manag Care 2009 0.75
20 Changing the organization of health care. JAMA 2007 0.75
21 Economic analysis of influenza vaccination and treatment. Ann Intern Med 2003 0.75
22 Depression and health-related quality of life. JAMA 2003 0.75
23 Lost in translation. N Engl J Med 2003 0.75
24 Substantial treatment overuse in the United States? Value Health 2007 0.75
25 Cost-effectiveness of cardioverter-defibrillators in heart failure patients. Europace 2009 0.75
26 The economic value of medical technology. Health Aff (Millwood) 2002 0.75
27 Ethical criteria for allocating health-care resources. Lancet 2009 0.75
28 Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2009 0.75
29 Productivity loss due to irritable bowel syndrome. Arch Intern Med 2003 0.75
30 Burden-of-disease estimates. Health Aff (Millwood) 2003 0.75
31 Economic evaluation of Sinfrontal in the treatment of acute maxillary sinusitis in adults. Appl Health Econ Health Policy 2009 0.75
32 Caregivers' quality of life and economic evaluations. Pharmacoeconomics 2012 0.75
33 Improving communication of health-related quality of life. JAMA 2003 0.75
34 Assessing the value of a future study. Pharmacoeconomics 2008 0.75
35 Educating authors and reviewers of economic evaluations of health care. JAMA 2002 0.75
36 Economic evaluations alongside equivalence and noninferiority trials. Value Health 2009 0.75
37 Educational epidemiology. JAMA 2004 0.75
38 Empirical validation of patient versus population preferences in calculating QALYs. Health Serv Res 2011 0.75
39 Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses. Eur J Health Econ 2014 0.75
40 Osteoporosis in German men: a cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res 2014 0.75
41 A 'centres of excellence' approach in health care: points for and against. Appl Health Econ Health Policy 2002 0.75